<DOC>
	<DOCNO>NCT02666573</DOCNO>
	<brief_summary>27 subject SPT , least two residual pocket ≥5mm , recruit randomise , split-mouth control trial , provide total 72 site . At baseline , probe pocket depth ( PPD ) , recession , clinical attachment level ( CAL ) , plaque bleed probing ( BOP ) sit examine . Gingival crevicular fluid ( GCF ) collect determine level cytokine IL-1β , -6 , -8 , TNF-α MMP-8 via ELISA . Control sit receive subgingival instrumentation rubber cup polish pumice . In addition test sit receive single application PDT use Fotosan® photosensitizer consist toludine blue O solution . The subject recall three six month later re-examined . Site level analysis perform .</brief_summary>
	<brief_title>Photodynamic Therapy During Supportive Periodontal Therapy</brief_title>
	<detailed_description />
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Periodontal Diseases</mesh_term>
	<mesh_term>Gingival Diseases</mesh_term>
	<mesh_term>Periodontal Attachment Loss</mesh_term>
	<criteria>1 . Good general health systemic disease cause manifestation periodontal diseases 2 . Age ≥ 21 year 3 . History chronic periodontitis 4 . At least two residual PPD ≥ 5 mm without bleed probe 5 . Compliant recall , i.e . last SPT visit 6 month start trial 6 . Able give write informed consent 1 . Pregnant lactating female 2 . Local systemic antibiotic intake past 3 month 3 . Systemic condition could affect progression periodontitis 4 . Long term use NSAIDs immunosuppressive medication 5 . Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>drug therapy</keyword>
	<keyword>Photosensitizing Agents</keyword>
	<keyword>therapeutic use</keyword>
</DOC>